Abstract

ObjectivesTo develop and evaluate machine learning models using baseline and restaging computed tomography (CT) for predicting and early detecting pathological downstaging (pDS) with neoadjuvant chemotherapy in advanced gastric cancer (AGC).MethodsWe collected 292 AGC patients who received neoadjuvant chemotherapy. They were classified into (a) primary cohort (206 patients with 3–4 cycles chemotherapy) for model development and internal validation, (b) testing cohort I (46 patients with 3–4 cycles chemotherapy) for evaluating models’ predictive ability before and after the complete course, and (c) testing cohort II (n = 40) for model evaluation on its performance at early treatment. We extracted 1,231 radiomics features from venous phase CT at baseline and restaging. We selected radiomics models based on 28 cross-combination models and measured the areas under the curve (AUC). Our prediction radiomics (PR) model is designed to predict pDS outcomes using baseline CT. Detection radiomics (DR) model is applied to restaging CT for early pDS detection.ResultsPR model achieved promising outcomes in two testing cohorts (AUC 0.750, p = .009 and AUC 0.889, p = .000). DR model also showed a good predictive ability (AUC 0.922, p = .000 and AUC 0.850, p = .000), outperforming the commonly used RECIST method (NRI 39.5% and NRI 35.4%). Furthermore, the improved DR model with averaging outcome scores of PR and DR models showed boosted results in two testing cohorts (AUC 0.961, p = .000 and AUC 0.921, p = .000).ConclusionsCT-based radiomics models perform well on prediction and early detection tasks of pDS and can potentially assist surgical decision-making in AGC patients.Key Points• Baseline contrast-enhanced computed tomography (CECT)-based radiomics features were predictive of pathological downstaging, allowing accurate identification of non-responders before therapy.• Restaging CECT-based radiomics features were predictive to achieve pDS after and even at an early stage of neoadjuvant chemotherapy.• Combination of baseline and restaging CECT-based radiomics features was promising for early detection and preoperative evaluation of pathological downstaging of AGC.

Highlights

  • Advanced gastric cancer (AGC) stands for 50–80% of all cases of gastric cancer (GC) [1]

  • Baseline contrast-enhanced computed tomography (CECT)-based radiomics features were predictive of pathological downstaging, allowing accurate identification of non-responders before therapy

  • Combination of baseline and restaging contrast-enhanced CT (CECT)-based radiomics features was promising for early detection and preoperative evaluation of pathological downstaging of advanced gastric cancer (AGC)

Read more

Summary

Introduction

Advanced gastric cancer (AGC) stands for 50–80% of all cases of gastric cancer (GC) [1]. The major amount of tumors (35–51%) fail to achieve pathological downstaging (pDS) after neoadjuvant chemotherapy and tumor progression was commonly observed (15%) [2, 3]. Early and accurate patient stratification would be helpful to select good candidates for neoadjuvant treatment of AGC patients. Computed tomography (CT) is routinely used for tumor monitoring over the course of treatment [4]. Baseline contrast-enhanced CT (CECT) is the preferred imaging examination to diagnose the TNM stage for gastric cancer before neoadjuvant chemotherapy in clinical practice. Restaging CECT evaluates tumor downstaging after neoadjuvant chemotherapy [4]. Low sensitivity (37–50%) of tumor size-based measurement [5] and inaccuracy (37–57%) of tumor restaging [6] by visual assessment are reported

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call